Endocrine Abstracts

Paltusotine is a once-daily, oral, nonpeptide somatostatin receptor type 2 (SST2) specific agonist, in development for the treatment of acromegaly and neuroendocrine tumors. We report interim results from ACROBAT Advance (NCT04261712), an ongoing, multicenter, open-label, long-term extension study of paltusotine in subjects with acromegaly who previously completed either Phase 2 study ACROBAT Edge (NCT03789656) or Evolve (NCT03792555). ACROBAT Edge enrolled 47 subjects with el...

Background: Hypoactive Sexual Desire Disorder (HSDD) is associated with dysfunctional brain activation in regions governing sexual responses, resulting in a deficiency/absence of sexual desire with marked distress. It affects up to 8% of men with detrimental effects on quality of life, interpersonal relationships and fertility, but so far has no licensed treatment options. The reproductive neuropeptide kisspeptin offers a putative therapeutic target owing to its emerging role ...

Introduction: Hypoactive sexual desire disorder (HSDD) is characterized by a persistent deficiency of sexual fantasies and desire for sexual activity, causing marked distress or interpersonal difficulty. It is the most prevalent female sexual health problem worldwide, affecting approximately 1 in 10 women, but has limited treatment options despite its substantial health, social, and economic burden. Melanocortin-4 receptor (MC4R) agonists have emerged as a promising therapy fo...

Background: Kisspeptin is a critical activator of hypothalamic gonadotrophin releasing hormone (GnRH) neurons and has significant potential to treat common reproductive disorders. To date, kisspeptin has solely been administered to humans via the intravenous or subcutaneous routes, however intranasal administration could offer a novel non-invasive delivery route. We therefore sought to determine the effects of intranasal kisspeptin on reproductive hormone release in humans for...

Introduction: Sexual desire is a key component of the sexual response model. Absence or deficiency of sexual desire can lead to marked distress or interpersonal difficulty, termed ‘hypoactive sexual desire disorder’ (HSDD). HSDD is the most common female sexual health complaint worldwide, affecting up to 10% of women. Despite its detrimental impact on psychological well-being and quality of life, treatment options are currently limited. The hormone kisspeptin is a ke...

Introduction: Resolution of pituitary tumour without surgical intervention is rare. The mechanism of spontaneous resolution of pituitary adenoma is unclear but may be explained by either pituitary apoplexy or hypophysitis responding to steroids. Bray BP, et al(2021) reported the case of vanishing pituitary mass due pituitary apoplexy. Park SM, et al (2014) reported 22 cases of pituitary mass due hypophysititis which improved mostly with medical therapy.C...

Hypoactive sexual desire disorder (HSDD) is a persistent lack of sexual desire, causing marked interpersonal distress. It is the most common global female sexual health problem, although the precise pathophysiology remains uncertain. Existing treatment options are limited by their efficacy and side effects. The neuropeptide kisspeptin offers a potential therapeutic target given its emerging role in modulating reproductive behaviour. Using a combination of psychometric, neuroim...

Background: 18F-fluorodeoxyglucose (18FDG) PET is commonly used to quantify brown adipose tissue (BAT) mass/activity in humans but requires cold exposure. Rodent brown (BAds) but not white adipocytes (WAds) exhibit high choline content, thus we hypothesised that human BAT would demonstrate substantial 18F-fluorocholine (18FCH) uptake in vivo during warm and cold conditions.Methods: (1)...

Background: Pheochromocytoma (PHEO) is a rare neuroendocrine tumor arising from chromaffin cells of adrenal gland that can cause life-threatening complications due to overproduction of catecholamines. Per EANM/SNMMI 2019 guidelines for radionuclide imaging of PHEO and paraganglioma, 18F-fluoro-L-dihydroxyphenylalanine (18F-FDOPA) is recommended as a positron emission tomography (PET) radiotracer of choice followed by 68Ga-DOTA(0)-Tyr(3)-octreot...

Background: The purpose of this prospective study was to evaluate and compare the detection rates of 18F-L-dihydroxyphenylalanine (18F-FDOPA), 68Ga-DOTATATE, 18F-FDG, and 18F-fluorodopamine (18F-FDA) PET or positron emission tomography/computed tomography (PET/CT), computed tomography (CT), and magnetic resonance imaging (MRI) in the detection of VHL-related pheochromocytoma (PHEO).<p class="abstext...